# S1800A (NCT03971474)

> Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

No report yet. It can be ordered.

- Drugs tested: ramucirumab plus pembrolizumab
- Indication: stage IV or recurrent non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03971474
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: SWOG Cancer Research Network
- Conditions: Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
- Interventions: Docetaxel; Gemcitabine; Gemcitabine Hydrochloride; Pembrolizumab; Pemetrexed; Pemetrexed Disodium; Ramucirumab
- Enrollment: 166
- Primary outcome: Overall Survival (OS)

## Indexed commentary on S1800A so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8
- Podcasts: 6
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=s1800a-nct03971474

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03971474", "email": "<work email>"}; the inbox owner confirms by the emailed link.